Maternal dietary fiber, short-chain fatty acids, and offspring developmental programming: a narrative review
This review synthesizes mechanisms by which maternal fiber-derived SCFAs modulate offspring metabolic and immune programming, but causal evidence in humans remains insufficient.
| Population | Pregnant women and their offspring (human and animal studies reviewed together) |
|---|---|
| Intervention | Maternal dietary fiber intake and/or SCFA supplementation |
| Comparator | Low-fiber diet or control condition (variable by primary study) |
| Outcome | Butyrate inhibition of HDAC3 (in vitro); NF-κB signaling during pregnancy (murine model); Body weight and metabolic parameters in offspring (murine model, paradoxical butyrate effect); Regulatory T cell (Treg) generation via HDAC inhibition; Neutrophil chemotactic activity (propionate, human placental tissue); Offspring metabolic programming in humans (clinical outcome); Preterm birth risk (propionate, via placental GPR41/43) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Butyrate inhibition of HDAC3 (in vitro) | IC50 0.318 mM (in vitro, in the CI reported) | — | Very low | — | 1 studies |
| NF-κB signaling during pregnancy (murine model) | reduction reported, in the quantitative estimate or CI provided | — | Very low | — | 1 studies |
| Body weight and metabolic parameters in offspring (murine model, paradoxical butyrate effect) | increase in body weight, glucose, insulin, triacylglycerol, cholesterol reported; in the quantitative estimate or CI provided | — | Very low | — | 1 studies |
| Regulatory T cell (Treg) generation via HDAC inhibition | mechanistic pathway described; in the quantitative human clinical estimate available | — | Very low | — | |
| Neutrophil chemotactic activity (propionate, human placental tissue) | reduction in neutrophil chemotaxis and IL-8 secretion reported; in the quantitative estimate or CI provided | — | Very low | — | 1 studies |
| Offspring metabolic programming in humans (clinical outcome) | no RCT or meta-analytic estimate available | — | Very low | — | |
| Preterm birth risk (propionate, via placental GPR41/43) | potential pathway described; in the quantitative clinical estimate available | — | Very low | — | 1 studies |
Context
Non-communicable diseases partly originate during the intrauterine period. The maternal gut microbiota ferments dietary fiber producing SCFAs (acetate, propionate, butyrate) that cross the placental barrier and may interfere with fetal development. Understanding these mechanisms is relevant for perinatal nutritional strategies.
What the study showed
The review describes mechanistically that butyrate inhibits HDACs (IC50 = 0.318 mM for HDAC3 in vitro), propionate regulates insulin via GPR43 and sympathetic development via GPR41 in mice, and acetate reaches systemic tissues modulating energy homeostasis. Mouse studies show butyric acid reduces NF-κB signaling during pregnancy, but with a paradoxical association with weight gain and elevated glucose, insulin, and lipids. No meta-analysis or human RCT on clinical outcomes in offspring is available.
How it was done
Non-systematic narrative mini-review. Integrates in vitro molecular data, animal model experiments (mainly mice), and human observational studies without formal quality screening, reproducible search strategy, or risk-of-bias assessment (RoB 2, ROBINS-I, and AMSTAR-2 not applied).
Effect magnitude
No consolidated effect size for clinical outcomes in offspring is reported. The only robust quantitative value is in vitro: IC50 of butyrate for HDAC3 = 0.318 mM.
Risk of bias
Narrative review without pre-registered protocol or formal risk-of-bias assessment (AMSTAR-2 not applicable due to absence of systematic methodology). Cross-species heterogeneity (mouse vs. human) limits extrapolation. Absence of dose-response data in pregnant humans. Paradoxical effects of butyrate in pregnant mice are not mechanistically explained.
What this study does NOT prove
This study does not prove causality between maternal fiber intake and health outcomes in human offspring. It does not generalize to populations with diets, microbiomes, or gestational conditions distinct from the studied models.
In clinical practice
Clinicians should not recommend SCFA supplementation in pregnant women based on this review. Adequate fiber intake during pregnancy follows general health recommendations, but specific benefits for offspring programming lack robust clinical evidence.
Limitations
Narrative review without pre-registered protocol or formal risk-of-bias assessment (AMSTAR-2 not applicable due to absence of systematic methodology). Cross-species heterogeneity (mouse vs. human) limits extrapolation. Absence of dose-response data in pregnant humans. Paradoxical effects of butyrate in pregnant mice are not mechanistically explained.
What is still missing
RCTs in pregnant humans evaluating offspring metabolic and immune outcomes with dietary fiber or prebiotic interventions are needed. Human placental pharmacokinetic studies of SCFAs are absent.
Technical appendix
Version history
- 1.0 · 2026-10-20 — Auto-generated under Evidence Standard v1.0